These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 14717973

  • 1. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
    Sørensen B, Ingerslev J.
    J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
    [Abstract] [Full Text] [Related]

  • 2. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
    Sørensen B, Persson E, Ingerslev J.
    Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
    [Abstract] [Full Text] [Related]

  • 3. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD, Holle LA, Wolberg AS.
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [Abstract] [Full Text] [Related]

  • 4. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S.
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [Abstract] [Full Text] [Related]

  • 5. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
    Sørensen B, Ingerslev J.
    Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
    [Abstract] [Full Text] [Related]

  • 6. Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.
    Li R, Panckeri KA, Fogarty PF, Cuker A, Diamond SL.
    Haemophilia; 2017 Sep; 23(5):759-768. PubMed ID: 28475272
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S, Sundaram J, Rajulapati A, Pendurthi UR, Rao LV.
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [Abstract] [Full Text] [Related]

  • 8. Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy.
    Johansen RF, Sørensen B, Ingerslev J.
    Haemophilia; 2006 Mar; 12(2):190-7. PubMed ID: 16476097
    [Abstract] [Full Text] [Related]

  • 9. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
    Livnat T, Zivelin A, Martinowitz U, Salomon O, Seligsohn U.
    J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
    [Abstract] [Full Text] [Related]

  • 10. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [Abstract] [Full Text] [Related]

  • 11. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
    Lisman T, de Groot PG, Lambert T, Røjkjaer R, Persson E.
    J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
    [Abstract] [Full Text] [Related]

  • 12. Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A.
    Rea CJ, Foley JH, Ingerslev J, Sørensen B.
    J Thromb Haemost; 2011 Mar; 9(3):510-6. PubMed ID: 21155966
    [Abstract] [Full Text] [Related]

  • 13. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D, Szlam F, Molinaro RJ, Escobar MA, Levy JH, Tanaka KA.
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [Abstract] [Full Text] [Related]

  • 14. Plasma-derived factors VIIa and X mixtures (Byclot®) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients.
    Ochi S, Takeyama M, Shima M, Nogami K.
    Int J Hematol; 2020 Jun; 111(6):779-785. PubMed ID: 32030609
    [Abstract] [Full Text] [Related]

  • 15. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
    Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M.
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
    [Abstract] [Full Text] [Related]

  • 16. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
    Carr ME, Martin EJ, Kuhn JG, Seremetis SV.
    Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
    [Abstract] [Full Text] [Related]

  • 17. Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis.
    Shima M.
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):125-31. PubMed ID: 14872433
    [Abstract] [Full Text] [Related]

  • 18. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
    Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Hedner U, Ezban M.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082
    [Abstract] [Full Text] [Related]

  • 19. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
    He S, Blombäck M, Jacobsson Ekman G, Hedner U.
    J Thromb Haemost; 2003 Jun; 1(6):1215-9. PubMed ID: 12871322
    [Abstract] [Full Text] [Related]

  • 20. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro.
    Yada K, Fujitate N, Ogiwara K, Soeda T, Kitazawa T, Nogami K.
    Thromb Res; 2024 May; 237():37-45. PubMed ID: 38547693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.